Glenmark Pharmaceuticals Limited

NSE GLENMARK.NS

Glenmark Pharmaceuticals Limited Capital Expenditure for the year ending March 31, 2024: USD -107.71 M

Glenmark Pharmaceuticals Limited Capital Expenditure is USD -107.71 M for the year ending March 31, 2024, a -45.65% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Glenmark Pharmaceuticals Limited Capital Expenditure for the year ending March 31, 2023 was USD -73.95 M, a 28.94% change year over year.
Glenmark Pharmaceuticals Limited Capital Expenditure for the year ending March 31, 2022 was USD -104.06 M, a 1.65% change year over year.
Glenmark Pharmaceuticals Limited Capital Expenditure for the year ending March 31, 2021 was USD -105.81 M, a 14.39% change year over year.
Glenmark Pharmaceuticals Limited Capital Expenditure for the year ending March 31, 2020 was USD -123.59 M, a 30.58% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NSE: GLENMARK.NS

Glenmark Pharmaceuticals Limited

CEO	Mr. Glenn Mario Saldanha
IPO Date	July 1, 2002
Location	India
Headquarters	Glenmark House
Employees	14,989
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Key trends

Past 5 years